

ERRATA
to
Hoffmann-La Roche's Briefing Document

Arthritis Advisory Committee
July 29, 2008

Sponsor's Briefing Package: Page 13, paragraph 2, sentence 2

“The data demonstrate that the 8 mg/kg dose offers the most reliable and consistent efficacy in all populations investigated and was the only dose that effectively controlled inflammation, as reflected by the C-reactive protein (CRP), throughout the 10-month dosing interval”.

Corrected to read:

“The data demonstrate that the 8 mg/kg dose offers the most reliable and consistent efficacy in all populations investigated and was the only dose that effectively controlled inflammation, as reflected by the C-reactive protein (CRP), throughout the **1-month** dosing interval”.

Sponsor's Briefing Package: Page 65, Table 27:

Summary of Adverse Events Reported in > 2% of Tocilizumab-treated Patients and with ≥ 1% Difference Control – Double-Blind Studies (Safety Population)

	TCZ 8 mg/kg N = 288	MTX N = 284	TCZ 4 mg/kg + DMARD N = 774	TCZ 8 mg/kg + DMARD N = 1582	Placebo + DMARD N = 1170
Preferred Term	%	%	%	%	%
URTI	7.3	5.3	7.8	6.2	6.1
Nasopharyngitis	6.9	6.0	5.6	4.3	4.4
Headache	7.3	2.5	5.3	5.8	3.4
Hypertension	5.6	2.1	4.4	4.1	2.7
Dizziness	3.1	1.4	3.1	1.9	1.7
Rash	2.4	1.4	3.3	3.9	1.3
Mouth ulceration	2.1	2.1	2.0	1.3	0.5
Gastritis	1.0	1.8	1.8	1.2	0.8
Increased transaminases*	8.3	8.8	5.9	5.0	4.5
Back pain	2.4	1.1	2.1	3.3	2.4
Cough	2.8	0.4	2.3	2.1	1.9
Pharyngolaryngeal pain	2.4	1.1	1.7	1.9	1.1
Bronchitis	3.1	2.1	3.2	4.3	3.2
Arthralgia	2.4	1.4	1.1	1.4	2.0

URTI = upper respiratory tract infection

*Increased AST, increased ALT, ALT abnormal, transaminase increased

Corrected to read:

Data in the fourth column (4 mg/kg + DMARD) and the fifth column (8 mg/kg + DMARD) were transposed, new terms were added and the footnote was amended. Gastritis has been deleted from the table as it had been included in error. The revised table reads as follows:

Summary of Adverse Events Reported in > 2% of Tocilizumab-treated Patients and with ≥ 1% Difference Control – Double-Blind Studies (Safety Population)

	TCZ 8 mg/kg N = 288	MTX N = 284	TCZ 4 mg/kg + DMARD N = 774	TCZ 8 mg/kg + DMARD N = 1582	Placebo + DMARD N = 1170
Preferred term	%	%	%	%	%
¹Increased transaminases	11.1	13.0	7.1	8.0	2.3
URTI	7.3	5.3	6.2	7.8	6.1
Nasopharyngitis	6.9	6.0	4.3	5.6	4.4
Bronchitis	3.1	2.1	4.3	3.2	3.2
²Abdominal pain	5.6	4.2	4.4	3.8	2.8
Mouth ulceration	2.1	2.1	1.3	2.0	0.5
Rash	2.4	1.4	3.9	3.3	1.3
Pruritus	2.8	1.1	1.4	1.6	0.9
Back pain	2.4	1.1	2.1	3.3	2.4
Arthralgia	2.4	1.4	1.4	1.1	2.0
Headache	7.3	2.5	5.8	5.3	3.4
Dizziness	3.1	1.4	1.9	3.1	1.7
Cough	2.8	0.4	2.1	2.3	1.9
Pharyngolaryngeal pain	2.4	1.1	1.9	1.7	1.1
Hypertension	5.6	2.1	4.1	4.4	2.7
Depression	2.1	0.7	1.0	1.3	1.2
Anxiety	2.4	0.7	0.6	0.8	0.8
Insomnia	2.1	1.1	2.1	1.0	1.3

URTI = upper respiratory tract infection

¹ includes increased ALT, increased transaminase, increased hepatic enzyme, abnormal liver function test, increased AST, abnormal ALT, ALT

² includes upper abdominal pain

Sponsor’s Briefing Package: Page 81, Section 7.6.3, paragraph 3, sentence 1

“Considering the Total Safety Exposure group (Table 42), six of the 19 patients with non-melanoma skin cancers had a previous history of a non-melanoma skin cancer of actinic keratosis.”

Corrected to read:

“Considering the Total Safety Exposure group (Table 42), six of the **22** patients with non-melanoma skin cancers had a previous history of a non-melanoma skin cancer of actinic keratosis.”

Sponsor’s Briefing Package: Page 82, Table 42

	TCZ 4 mg/kg + DMARD PY=435 n (rate/100 PY)	TCZ 8 mg/kg +/- DMARD PY=3707 n (rate/100 PY)	Placebo PY=628 n (rate/100 PY)	ALL TCZ PY=4142 n (rate/100 PY)	Chugai (N=957) PY=2009 n (rate/100 PY)
Non-melanoma Skin cancer	2 (0.46)	4 (0.11)	2* (0.32)	22 (0.53)	NA

Corrected to read:

	TCZ 4 mg/kg + DMARD PY=435 n (rate/100 PY)	TCZ 8 mg/kg +/- DMARD PY=3707 n (rate/100 PY)	Placebo PY=628 n (rate/100 PY)	ALL TCZ PY=4142 n (rate/100 PY)	Chugai (N=957) PY=2009 n (rate/100 PY)
Non-melanoma Skin cancer	2 (0.46)	20 (0.54)	2* (0.32)	22 (0.53)	NA